News | 30 December 2021
Biological E gets nod to study Corbevax as a booster dose
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Aim of the virtual conference is to facilitate Indian Pharma Industry adopt Green & Sustainable Chemistry as a tool to enhance Economic & Environmental Competitiveness
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
The facility at the Andhra Pradesh Medtech Zone is expected to be completed by Dec 2022
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Flattish volume growth and subdued new launches were key factors for last month
The single-dose vaccine has been approved in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination
The company has started manufacturing the Sputnik Light vaccine
Sputnik Light as a booster significantly increases virus-neutralizing activity against Omicron based on sera 2-3 months after revaccination and is a universal booster to other vaccines inducing stronger antibody and T-cell response
The company will collaborate with U.S.-based colleagues to help life sciences companies improve commercial effectiveness
The Indian Council of Medical Research (ICMR), intends to enter into non-exclusive agreements with companies
Authorized booster increases Omicron neutralizing antibody levels approximately 37-fold
TeleRay partners with Radiobotics, adding Artificial Intelligence to their pre-existing integrated best-in-class medical image and patient information distribution platform
Subscribe To Our Newsletter & Stay Updated
